vascular therapies inc private company information  bloomberg july    pm et healthcare equipment and supplies company overview of vascular therapies inc snapshot people company overview vascular therapies inc designs develops and manufactures vascular device under the name collr the company was founded in  and is headquartered in cresskill new jersey  union avenuecresskill nj united statesfounded in  phone  vasculartherapiesnet key executives for vascular therapies inc dr sriram s iyer md chairman and president compensation as of fiscal year  vascular therapies inc key developments vascular therapies inc presents at th annual jp morgan healthcare conference jan  am jan   vascular therapies inc presents at th annual jp morgan healthcare conference jan  am venue westin st francis hotel  powell street san francisco ca  united states speakers sriram s iyer chairman and president similar private companies by industry company name region decimal inc united states  genesystems inc united states  imaging llc united states st century scientific inc united states x corporation united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact vascular therapies inc please visit vasculartherapiesnet company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close sirogen trademark of vascular therapies inc serial number   trademarkia trademarks apply online attorneys services us trademark registration service international trademark registration service trademark office action response trademark statement of use trademark renewal trademark assignment trademark watch trademark cease  desist trademark comprehensive search copyright registration patent services incorporation services business page creation more services help contact us login trademark search trademark category pharmaceutical products sirogen   get free email alerts sirogen trademark information vascular therapies inc a combination drug product namely a formulation of sirolimus incorporated within a collagen membrane which as an implantable drug carrier enables local delivery of sirolimus to the vascular wall perfect for these industries pharmaceutical products words that describe this mark combination   drug   product       formulation   sirolimus   incorporated   collagen   membrane       implantable   drug   carrier     enables   local   delivery   sirolimus   vascular   wall   this is a brand page for the sirogen trademark by vascular therapies inc  in cresskill nj  write a review about a product or service associated with this sirogen trademark or contact the owner vascular therapies inc of the sirogen trademark by filing a request to communicate with the legal correspondent for licensing use andor questions related to the sirogen trademark on tuesday january   a us federal trademark registration was filed for sirogen by vascular therapies inc cresskill nj  the uspto has given the sirogen trademark serial number of  the current federal status of this trademark filing is abandoned  no statement of use filed the correspondent listed for sirogen is michael bamberger of beck chaet bamberger  polsky sc  e kilbourn ave ste  milwaukee wi   the sirogen trademark is filed in the category of pharmaceutical products  the description provided to the uspto for sirogen is a combination drug product namely a formulation of sirolimus incorporated within a collagen membrane which as an implantable drug carrier enables local delivery of sirolimus to the vascular wall word mark sirogen statusstatus date abandoned  no statement of use filed  serial number  filing date  registration number not available registration date not available goods and services a combination drug product namely a formulation of sirolimus incorporated within a collagen membrane which as an implantable drug carrier enables local delivery of sirolimus to the vascular wall mark description not available type of mark trademark published for opposition date  last applicantowner vascular therapies inccresskill nj  why is this contact information displayed why is this contact information displayed close the uspto makes this data available for search by the public so that individuals can locate ownership information for intellectual property much the same way a county might make real estate property ownership information available since our website is synchronized with the uspto data we recommend making any data changes with the uspto directly our website will autoupdate when the uspto data is updated you may also contact trademarkia to make a request for the removal of your personally identifiable information or trademark data such requests must be made in writing and will be subject to verification of ownership this policy allows verified trademark owners to specify a that their identifiable information be masked or b that their trademark pages permanently deleted from trademarkiacom requests may be made directly to customerservicetrademarkiacom and every effort will be made to honor them within  hours click here for further details close mark drawing code standard character mark design search no data register type principal disclaimer not available correspondent michael bamberger beck chaet bamberger  polsky sc  e kilbourn ave ste  milwaukee wi  intent to use trademark  applicant has not submitted proof of use in commerce the the uspto classification information primary class class   pharmaceutical and veterinary preparations sanitary preparations for medical purposes dietetic substances adapted for medical use food for babies plasters materials for dressings material for stopping teeth dental wax disinfectants preparations for destroying vermin fungicides herbicides first use anywhere not provided first use in commerce not provided trademarkia is the largest search engine for us trademarks each month hundreds of trademarks around the world are filed by licensed attorneys in the legalforcetrademarkia network you can register your trademark in  countries in the world through legalforce network legalforce network can help you incorporate a business around your sirogen trademark in less than  minutes trademarkia makes the process easy and convenient so start now trademarkiacom is a free search engine of publicly available government records trademarkiacom is not a law firm and does not represent owners  correspondents listed on this page trademark document retrieval  trademark  apply online  satisfaction guarantee protect your valuable brand now how it works what you get  legalforce rapc   us trademark filing from  to now  describe how your business or product is being used register your mark in  countries just   govt fees start here   top global ip attorneys  credibility and experience  all processes will be performed in a timely manner you will be informed periodically about the process keep track of this brand trademark watch services keep track of how your trademark is being used available in the united states and in more than  countries roundtheclock monitoring monthly report on potential infringement watch this trademark trademark watch services read more current trademark status  abandoned  no statement of use filed free trademark search correspondent search michael bamberger is a correspondent of sirogen trademark current overall rating  review what you can do start your business free logo creator add to favorites view documents free trademark search start trademark filing process protect this mark internationally custom logo design  search sirogen on popular social networks trademarkia lets you see how your personal name product name trademark name or username is being used on any of  new and popular social networks be the first to reserve your name and get help stopping others from using it  all in one place trademark oppose service you can request for extension of time to oppose this mark or oppose it now  if you are new to legalforcetrademarkia please just enter your contact email and create a password  if you already have a legalforcetrademarkia account please enter your accounts email and password  email address please enter your email address  enter password please enter your password  please enter the value       status update alerts status update alerts are email updates of the latest trademark status change please make sure you provide the correct email  if you are new to legalforcetrademarkia please just enter your contact email and create a password  if you already have a legalforcetrademarkia account please enter your accounts email and password  email address please enter your email address  enter password please enter your password  please enter the value       review  rating please rate and review for sirogen sirogen is providing a combination drug product namely a formulation of sirolimus incorporated within a collagen membrane which as an implantable drug carrier enables local delivery of sirolimus to the vascular wall  if you are new to legalforcetrademarkia please just enter your contact email and create a password to be associated with your review if you already have a legalforcetrademarkia account please enter your accounts email and password before posting your review  please rate        your review please enter your review  email address please enter your email address  enter password please enter your password       microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft cardiovascular products  healthcare professionals  medtronic your browser is out of date with an updated browser you will have a better medtronic website experience update my browser now × skip to main content adriatic argentina asiapacific australia and new zealand belgium  français belgium  nederlands bolivia brasil brazil bulgaria canada  english canada  français česká republika czech republic chile  china colombia costa rica србија serbia danmark denmark deutschland germany ecuador españa spain europe france global ελλάδα greece indian subcontinent ireland israel  ישראל italia italy  japan latinoamérica magyarország hungary méxico mexico middle east and north africa nederland netherlands norge norway österreich austria panama paraguay perú peru polska poland portugal российская федерация russia puerto rico romania schweiz switzerland  deutsch slovenská republika slovak republic south africa and subsahara 대한민국 south korea southeast asia suisse switzerland  français suomi finland sverige sweden türkiye turkey united kingdom united states uruguay venezuela україна ukraine menu close search close go advanced search tips cardiovascular products information for healthcare professionals cardiac products ablation products – surgical aortic stent grafts blood management and diagnostics cannulae cardiopulmonary products cardiothoracic products coronary balloons coronary catheters coronary stents electrosurgical products embolic protection system heart valves – surgical heart valves – transcatheter interventional guidewires and accessories  pediatric perfusion products revascularization products surgical transradial experience learn about related therapies  procedures access clinician information lifeline cardiovascular technical support   rscstechsupportmedtroniccom reimbursement hotline vascular therapies  structural heart therapies  rscardiovascularhealtheconomicsmedtroniccom visit our website var datalayer    sm  adding tracker for dynamic form  end  vascular therapies  innovative treatments for dialysis patients homecurrent focusprogress to dateabout usabout vascular therapiesmanagement teamsriram iyer md facc fscairosanne terracianodavid kornhauser eddrakesh raghubanshipaul barkofsky phdmaureen harrisonboard of directorsrobert crocemichael bamberger esqgerald dorros mdrobert flanagansriram iyer md facc fscaisomu subramaniamkiyoshi takesueallan r tesslercontact us vascular therapies   infovasculartxcom about vascular therapies glenn t about vascular therapies vascular therapies a focused experienced and passionate team driven by the goal of improving the lives of patients vascular therapies vt is a biopharmaceutical company committed to the development and commercialization of innovative new treatments to address major unmet clinical needs of patients requiring an av fistula for dialysis our lead product candidate containing sirolimus has received orphan drug designations in the us and eu for the dialysis vascular access indications the company consists of a focused experienced and passionate team driven by the goal of improving the lives of patients we take pride in strong global relationships with the patient research and medical communities the current development plan is focused on the hemodialysis vascular access indication – investigating the safety and usefulness of the drug product to improve the outcomes of an arteriovenous fistula avf the company is conducting its us phase  randomized avf clinical trial in accordance with a special protocol assessment spa agreement with the us fda meet our management team meet our board of directors caution the sirolimuseluting collagen implant is an investigational product that is not available for sale in any country read our expanded access policy safety and efficacy of the sirolimuseluting collagen implant to assess av fistula outcomes in patients on hemodialysis  full text view  clinicaltrialsgov skip to main content this site became the new clinicaltrialsgov on june th learn more show more we will be updating this site in phases this allows us to move faster and to deliver better services show less important listing of a study on this site does not reflect endorsement by the national institutes of health talk with a trusted healthcare professional before volunteering for a study read more important talk with a trusted healthcare professional before volunteering for a study read more a service of the us national institutes of health × find studies new search advanced search see studies by topic see studies on map how to search how to use search results how to find results of studies how to read a study record about studies learn about studies other sites about studies glossary of common site terms submit studies why should i register and submit results fdaaa  requirements how to apply for an account how to register your study how to edit your study record how to submit your results frequently asked questions support materials training materials resources selected publications clinical alerts and advisories rss feeds trends charts and maps downloading content for analysis about site clinicaltrialsgov background about the results database history policies and laws mediapress resources linking to this site terms and conditions disclaimer saved studies saved studies  give us feedback find studies new search advanced search see studies by topic see studies on map how to search how to use search results how to find results of studies how to read a study record about studies learn about studies other sites about studies glossary of common site terms submit studies why should i register and submit results fdaaa  requirements how to apply for an account how to register your study how to edit your study record how to submit your results frequently asked questions support materials training materials resources selected publications clinical alerts and advisories rss feeds trends charts and maps downloading content for analysis about site clinicaltrialsgov background about the results database history policies and laws mediapress resources linking to this site terms and conditions disclaimer home study record detail safety and efficacy of the sirolimuseluting collagen implant to assess av fistula outcomes in patients on hemodialysis access this study is currently recruiting participants see contacts and locations verified august  by vascular therapies inc sponsor vascular therapies inc information provided by responsible party vascular therapies inc clinicaltrialsgov identifier nct first received july   last updated august   last verified august  history of changes full text view tabular view no study results posted disclaimer how to read a study record   purpose the purpose of this study is to determine whether the use of the sirolimuseluting collagen implant will improve av fistula outcomes including time to first dialysis and suitability for dialysis at  months in subjects undergoing surgical creation of an av fistula for providing vascular access for hemodialysis condition intervention phase complication of renal dialysis end stage renal disease end stage kidney disease esrd chronic kidney failure complication of hemodialysis vascular access complication arteriovenous fistula drug sirolimus phase  study type interventional study design allocation randomizedintervention model parallel assignmentmasking double blind participant care provider outcomes assessorprimary purpose prevention official title a phase  randomized multicenter singleblind controlled study evaluating arteriovenous fistula outcomes with and without a perivascular sirolimuseluting collagen implant in subjects on hemodialysis resource links provided by nlm medlineplus related topics dialysis fistulas drug information available for sirolimus everolimus temsirolimus us fda resources further study details as provided by vascular therapies inc primary outcome measures time to first dialysis ttfd  time frame assessments to determine the suitability for first cannulation of the av fistula will start  days following surgery time to first dialysis ttfd defined as the time from fistula creation to the time when the fistula can support three consecutive dialysis sessions using needles with a mean dialysis machine blood pump speed of ≥ mlmin secondary outcome measures fistula suitability for dialysis at  months fsd  time frame assessed during a day suitability ascertainment period that begins  days after fistula creation fistula suitability for dialysis at  months fsd defined as the ability to use the fistula for dialysis using needles with a mean dialysis machine blood pump speed of ≥ mlmin for twothirds of the dialysis sessions during a  day suitability ascertainment period that begins  days after fistula creation estimated enrollment  study start date november  estimated study completion date december  estimated primary completion date june  final data collection date for primary outcome measure arms assigned interventions experimental treatment group av fistula surgery with investigational product sirolimuseluting collagen implant drug sirolimus subjects in the treatment group will receive a single prophylactic dose of sirolimus delivered locally to the vessel wall at and around the site of the anastomosis of an av fistula immediately following completion of a successful av fistula surgery control group subjects will have surgery for creation of the av fistula but will not receive the drug other name rapamycin no intervention control group av fistula surgery without investigational product   eligibility ages eligible for study    years and older   adult senior sexes eligible for study   all accepts healthy volunteers   no criteria inclusion criteria currently on hemodialysis for ≤ months vascular anatomy suitable for creation of the av fistula determined by pre procedure duplex ultrasound successful creation of a single stage radiocephalic or brachiocephalic end to side fistula exclusion criteria prior av access created on the limb where the fistula surgery is planned stelevation mi or cerebrovascular accident within  days of the index procedure known hypersensitivity to the following sirolimus beef or bovine collagen hypotension with systolic blood pressures  mm hg at the time of screening known or suspected active infection at the time of the av fistula surgery known to be hiv positive prisoner mentally incompetent andor alcohol or drug abuser   contacts and locations choosing to participate in a study is an important personal decision talk with your doctor and family members or friends about deciding to join a study to learn more about this study you or your doctor may contact the study research staff using the contacts provided below for general information see learn about clinical studies please refer to this study by its clinicaltrialsgov identifier nct contacts contact rakesh raghubanshi  rakeshvasculartxcom contact david kornhauser edd  davidvasculartxcom locations united states alabama nephrology consultants llc recruiting huntsville alabama united states  contact rakesh raghubanshi        rakeshvasculartxcom    united states arizona akdhc medical research service recruiting phoenix arizona united states  contact rakesh raghubanshi        rakeshvasculartxcom    united states california san diego institute of medical research recruiting escondido california united states  contact rakesh raghubanshi        rakeshvasculartxcom    united states pennsylvania northeast clinical research center recruiting bethlehem pennsylvania united states  contact rakesh raghubanshi        rakeshvasculartxcom    sponsors and collaborators vascular therapies inc investigators study director sriram iyer md vascular therapies inc   more information responsible party vascular therapies inc clinicaltrialsgov identifier nct     history of changes other study id numbers vt study first received july   last updated august   keywords provided by vascular therapies inc dialysis end stage renal disease end stage kidney disease esrd chronic kidney failure chronic renal failure chronic kidney disease hemodialysis vascular access arteriovenous fistula av fistula avf nephrology vascular surgery dialysis access additional relevant mesh terms kidney diseases kidney failure chronic renal insufficiency chronic fistula renal insufficiency arteriovenous fistula urologic diseases pathological conditions anatomical arteriovenous malformations vascular malformations cardiovascular abnormalities cardiovascular diseases vascular fistula vascular diseases congenital abnormalities sirolimus everolimus antibacterial agents antiinfective agents antibiotics antineoplastic antineoplastic agents antifungal agents immunosuppressive agents immunologic factors physiological effects of drugs clinicaltrialsgov processed this record on july   to top for patients and families for researchers for study record managers home rss feeds site map terms and conditions disclaimer customer support copyright privacy accessibility viewers and players freedom of information act usagov us national library of medicine us national institutes of health us department of health and human services vascular therapies inc  jacksonville  fl  company information products resources my account talk to a db advisor  business directory fl jacksonville business services nec business services at noncommercial site vascular therapies inc v vascular therapies inc claim this business  nandina ln jacksonville fl  get directions   business info founded  incorporated annual revenue  employee count  industries business services at noncommercial site contacts eric a williams contact business your email address subject message send message company summary vascular therapies inc was founded in  vascular therapies inc specializes in business services at noncommercial site verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   v view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocalcom mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call  to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved vascular therapies  local drug delivery to address unmet clinical needs homecurrent focusprogress to dateabout usabout vascular therapiesmanagement teamsriram iyer md facc fscairosanne terracianodavid kornhauser eddrakesh raghubanshipaul barkofsky phdmaureen harrisonboard of directorsrobert crocemichael bamberger esqgerald dorros mdrobert flanagansriram iyer md facc fscaisomu subramaniamkiyoshi takesueallan r tesslercontact us vascular therapies   infovasculartxcom loading vascular therapies harnessing local drug delivery to address unmet clinical needs watch video home glenn t the kidney patient’s unmet clinical need a growing problemchronic kidney disease ckd is a serious and growing health problem affecting  in  american adults end stage renal disease esrd is the final stage of ckd a patient with esrd has kidney failure and unless the lost kidney function is replaced esrd is fatalreplacing lost functionworldwide about  of patients with esrd depend on hemodialysis to replace their lost kidney function and patients generally undergo dialysis treatment three times a weekthe need for a better solutionto prepare the patient for dialysis a surgeon connects an artery and a vein in the forearm or upper arm this connection is called a “vascular anastomosis” this vascular access a portal of entry into the vascular system is intended to allow for the consistent high flow of blood necessary for dialysis often this approach fails putting the patient’s health — even life — in dangerhow vascular therapies is addressing the need local drug delivery vascular therapies’ approach is to deliver sirolimus a drug locally to the blood vessel at and around the anastomosis it is doing so by implanting a collagenbased drug delivery system containing sirolimus at the time of the surgical procedure vascular therapies’ goal to prevent the veins from narrowing keep the portal open and provide for consistent vascular access necessary for successful dialysis vascular therapies’ promising clinical trial results vascular therapies is currently conducting a phase  randomized multicenter study in the united states it’s designed to test the efficacy and safety of the sirolimuseluting collagen implant outcomes of the company’s phase  clinical study supported safety feasibility and provided a signal for efficacy learn more ×wed love to hear from you fill out the form and our team will be in touch with you promptly thank you for your interest  north west street new york city ny   infoyourdomaincom wwwyourdomaincom your name required your email required subject your message closecaution the sirolimuseluting collagen implant is an investigational product that is not available for sale in any country read our expanded access policy